The rise of Viagra and its influence on the medicinal landscape presents a complex question for investors. While the first sales data were astounding, the intellectual property has lapsed, leading to a flood of generic alternatives that are chipping away at revenue. In addition, the sector is facing issues related to population trends and shifting